Pulse Biosciences [PLSE] vs Becton, Dickinson [BDX] Detailed Stock Comparison
Pulse Biosciences
NASDAQ
Loading...
Becton, Dickinson
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Pulse Biosciences wins in 4 metrics, Becton, Dickinson wins in 11 metrics, with 0 ties. Becton, Dickinson appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Pulse Biosciences | Becton, Dickinson | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -17.36 | 35.89 | Pulse Biosciences |
| Price-to-Book Ratio | 10.21 | 2.21 | Becton, Dickinson |
| Debt-to-Equity Ratio | 7.89 | 75.93 | Pulse Biosciences |
| PEG Ratio | -0.43 | 1.88 | Pulse Biosciences |
| EV/EBITDA | -13.63 | 12.63 | Pulse Biosciences |
| Profit Margin (TTM) | 0.00% | 7.41% | Becton, Dickinson |
| Operating Margin (TTM) | 0.00% | 17.81% | Becton, Dickinson |
| EBITDA Margin (TTM) | N/A | 17.81% | N/A |
| Return on Equity | -103.50% | 6.18% | Becton, Dickinson |
| Return on Assets (TTM) | -56.19% | 3.96% | Becton, Dickinson |
| Free Cash Flow (TTM) | $-36.47M | $3.07B | Becton, Dickinson |
| Dividend Yield | N/A | 1.80% | N/A |
| 1-Year Return | -25.51% | -16.82% | Becton, Dickinson |
| Price-to-Sales Ratio (TTM) | N/A | 2.63 | N/A |
| Enterprise Value | $968.93M | $74.75B | Becton, Dickinson |
| EV/Revenue Ratio | N/A | 3.50 | N/A |
| Gross Profit Margin (TTM) | N/A | 47.81% | N/A |
| Revenue per Share (TTM) | $0 | $74 | Becton, Dickinson |
| Earnings per Share (Diluted) | $-1.08 | $5.47 | Becton, Dickinson |
| Beta (Stock Volatility) | 1.60 | 0.22 | Becton, Dickinson |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Pulse Biosciences vs Becton, Dickinson Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Pulse Biosciences | 6.81% | -7.57% | 6.88% | -7.51% | -17.82% | -10.06% |
| Becton, Dickinson | 1.53% | 0.84% | 12.15% | 13.57% | -13.54% | -13.18% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Pulse Biosciences | -25.51% | 1,130.77% | 63.10% | 287.41% | 287.41% | 287.41% |
| Becton, Dickinson | -16.82% | -22.50% | -16.99% | 41.11% | 189.08% | 284.34% |
Performance & Financial Health Analysis: Pulse Biosciences vs Becton, Dickinson
| Metric | PLSE | BDX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.07B | $56.27B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 197,590 | 2,951,116 |
| 90 Day Avg. Volume | 162,470 | 3,001,469 |
| Last Close | $17.09 | $199.64 |
| 52 Week Range | $13.77 - $25.00 | $163.33 - $251.99 |
| % from 52W High | -31.64% | -20.77% |
| All-Time High | $45.82 (Feb 08, 2021) | $287.32 (Jul 24, 2023) |
| % from All-Time High | -62.70% | -30.52% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.10% |
| Quarterly Earnings Growth | N/A | 0.18% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.07% |
| Operating Margin (TTM) | 0.00% | 0.18% |
| Return on Equity (TTM) | -1.04% | 0.06% |
| Debt to Equity (MRQ) | 7.89 | 75.93 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.55 | $88.87 |
| Cash per Share (MRQ) | $1.58 | $2.64 |
| Operating Cash Flow (TTM) | $-44,496,000 | $3.25B |
| Levered Free Cash Flow (TTM) | $-21,688,876 | $3.37B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.80% |
| Last 12-Month Dividend | N/A | $3.03 |
Valuation & Enterprise Metrics Analysis: Pulse Biosciences vs Becton, Dickinson
| Metric | PLSE | BDX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -17.36 | 35.89 |
| Forward P/E | -17.62 | 12.48 |
| PEG Ratio | -0.43 | 1.88 |
| Price to Sales (TTM) | N/A | 2.63 |
| Price to Book (MRQ) | 10.21 | 2.21 |
| Market Capitalization | ||
| Market Capitalization | $1.07B | $56.27B |
| Enterprise Value | $968.93M | $74.75B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 3.50 |
| Enterprise to EBITDA | -13.63 | 12.63 |
| Risk & Other Metrics | ||
| Beta | 1.60 | 0.22 |
| Book Value per Share (MRQ) | $1.55 | $88.87 |
Financial Statements Comparison: Pulse Biosciences vs Becton, Dickinson
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PLSE | BDX |
|---|---|---|
| Revenue/Sales | $0 | $5.27B |
| Cost of Goods Sold | N/A | $3.02B |
| Gross Profit | N/A | $2.26B |
| Research & Development | $10.31M | $302.00M |
| Operating Income (EBIT) | $-18.04M | $637.00M |
| EBITDA | $-17.76M | $1.21B |
| Pre-Tax Income | $-16.80M | $363.00M |
| Income Tax | $0 | $55.00M |
| Net Income (Profit) | $-16.80M | $308.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PLSE | BDX |
|---|---|---|
| Cash & Equivalents | $119.28M | $667.00M |
| Total Current Assets | $120.91M | $8.67B |
| Total Current Liabilities | $7.76M | $7.69B |
| Long-Term Debt | $7.17M | $17.67B |
| Total Shareholders Equity | $118.45M | $25.24B |
| Retained Earnings | $-407.30M | $16.15B |
| Property, Plant & Equipment | $8.25M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PLSE | BDX |
|---|---|---|
| Operating Cash Flow | $-10.20M | $941.00M |
| Capital Expenditures | $-45,000 | N/A |
| Free Cash Flow | $-13.57M | $35.00M |
| Debt Repayment | N/A | $-1.00M |
| Common Stock Repurchase | N/A | $0 |
Short Interest & Institutional Ownership Analysis
| Metric | PLSE | BDX |
|---|---|---|
| Shares Short | 2.45M | 5.48M |
| Short Ratio | 15.22 | 1.90 |
| Short % of Float | 0.16% | 0.02% |
| Average Daily Volume (10 Day) | 197,590 | 2,951,116 |
| Average Daily Volume (90 Day) | 162,470 | 3,001,469 |
| Shares Outstanding | 65.93M | 289.10M |
| Float Shares | 17.44M | 285.99M |
| % Held by Insiders | 0.74% | 0.01% |
| % Held by Institutions | 0.09% | 0.92% |
Dividend Analysis & Yield Comparison: Pulse Biosciences vs Becton, Dickinson
| Metric | PLSE | BDX |
|---|---|---|
| Last 12-Month Dividend | N/A | $3.03 |
| Last 12-Month Dividend Yield | N/A | 1.80% |
| 3-Year Avg Annual Dividend | N/A | $3.16 |
| 3-Year Avg Dividend Yield | N/A | 0.40% |
| 3-Year Total Dividends | N/A | $9.48 |
| Ex-Dividend Date | N/A | Mar 10, 2025 |